Gilead Sciences

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GILD and other ETFs, options, and stocks.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
14,400
Employees14,400
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
14,400
Employees14,400

GILD Key Statistics

Market cap
111.55B
Market cap111.55B
Price-Earnings ratio
33.83
Price-Earnings ratio33.83
Dividend yield
3.24
Dividend yield3.24
Average volume
7.79M
Average volume7.79M
High today
$89.24
High today$89.24
Low today
$88.30
Low today$88.30
Open price
$89.02
Open price$89.02
Volume
3.79M
Volume3.79M
52 Week high
$89.61
52 Week high$89.61
52 Week low
$57.17
52 Week low$57.17

GILD News

Investor's Business Daily 3h
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Recent initial public offering Arcellx (ACLX) forged a $325 million multiple myeloma deal with Gilead Sciences (GILD) on Friday, and the IPO stock broke out. X...

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
MarketWatch 5h
Gilead to co-develop Arcellx's multiple myeloma drug

Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, whi...

Gilead to co-develop Arcellx's multiple myeloma drug
MarketWatch 5h
Arcellx, Gilead Ink Multiple Myeloma Collaboration >ACLX GILD - MarketWatch

By Colin Kellaher Arcellx Inc. and Gilead Sciences Inc. on Friday said they agreed to co-develop and co-commercialize Arcellx's lead late-stage product candida...

Arcellx, Gilead Ink Multiple Myeloma Collaboration >ACLX GILD - MarketWatch

Analyst ratings

57%

of 30 ratings
Buy
43.3%
Hold
56.7%
Sell
0%

GILD Earnings

$0.00
$0.88
$1.77
$2.65
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Jan 31, After Hours
ActualExpected Jan 31, After Hours

More GILD News

Yahoo Finance 6h
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma - Yahoo Finance

-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- A...

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma - Yahoo Finance
Simply Wall St 7h
Do These 3 Checks Before Buying Gilead Sciences, Inc. For Its Upcoming Dividend - Simply Wall St

Gilead Sciences, Inc. ( ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day before the record date, which is the cut-off d...

Do These 3 Checks Before Buying Gilead Sciences, Inc. For Its Upcoming Dividend - Simply Wall St
Simply Wall St 7h
Don't Race Out To Buy Gilead Sciences, Inc. Just Because It's Going Ex-Dividend

It looks like Gilead Sciences, Inc. (NASDAQ:GILD) is about to go ex-dividend in the next four days. The ex-dividend date is one business day before the record d...

Don't Race Out To Buy Gilead Sciences, Inc. Just Because It's Going Ex-Dividend
Benzinga 21h
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 15 Years - Gilead Sciences ( - Benzinga

Gilead Sciences GILD has outperformed the market over the past 15 years by 2.68% on an annualized basis producing an average annual return of 9.5%. Currently, G...

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 15 Years - Gilead Sciences ( - Benzinga
Simply Wall St 2d
Should Gilead Sciences, Inc. Focus On Improving This Fundamental Metric?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about R...

Should Gilead Sciences, Inc. Focus On Improving This Fundamental Metric?
Yahoo Finance 2d
The Zacks Analyst Blog Highlights Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands - Yahoo Finance

For Immediate Release Chicago, IL – December 7, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research...

The Zacks Analyst Blog Highlights Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands - Yahoo Finance
Yahoo Finance 3d
Should You Consider Adding Gilead Sciences to Your Portfolio? - Yahoo Finance

Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter investor letter. A copy of the same can be downloaded here....

Should You Consider Adding Gilead Sciences to Your Portfolio? - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.